+
No debt
Close to casflow neutral/positive
fairly Stable and high top 20 %
Billionaire tops up 2m @ 20c
Increasing sales Q on Q
-
Lacks liquidity
Needs better PR from company (take example horse nebulizer, no announcement), CEO role stil effectively vacant.
A couple new hirings to management and shuffle of board (Delk)
Lack of breakdown and insight into medivet business
Overall, 100% better on where they were 12-18mths back. I can see the concern for some, hence the SP halving, however the turnover has been lackluster, it doesn't look like the big holders running for the exits... I personally sit on a bundle.of these and have no intention of selling. Happy for this to be my LT biotech holding, but each to there own, dyor etc.
Cheers
Add to My Watchlist
What is My Watchlist?